Skip to content

Clinical trials

Observational Giant Cell Arteritis trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Giant Cell Arteritis Phase: Observational Country / region: France Clear all

26 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20091
20111
20121
20131
20141
20151
20171
20181
20192
20205
20211
20221
20232
20243
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed12
Recruiting6
Unknown status3
Not yet recruiting2
Terminated2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Centre Hospitalier Universitaire Dijon5
University Hospital, Brest4
Fondation Ophtalmologique Adolphe de Rothschild3
Groupe français d'étude des Maladies Inflammatoires de loeil3
Central Hospital, Nancy, France1
Centre Hospitalier Universitaire de Nīmes1
Centre Hospitalier William Morey - Chalon sur Saône1
Chugai Pharma France1
Groupe Hospitalier de la Rochelle Ré Aunis1
Hôpital NOVO1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Giant Cell Arteritis26
Polymyalgia Rheumatica3
Vasculitis2
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis1
Aortitis1
Arthritis, Rheumatoid1
Axial Spondyloarthritis1
COVID-191
Cardiovascular Diseases1
Churg-Strauss Syndrome1

Trials

Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.